Objective To investigate the clinical efficacy of deep cervical lymphatic-venous anastomosis (dcLVA) in the treatment of Parkinson's disease, evaluating postoperative improvements in both motor and cognitive impairments in patients with Parkinson's disease. Methods From April 2024 to December 2024, 8 patients with Parkinson's disease underwent dcLVA at Chashan Hospital in Dongguan. Under indocyanine green (ICG) fluorescence navigation, the deep cervical lymphatic system was visualized. Lymphatic vessels in ICG-stained cervical lymph node zones II and III were selected for end-to-end anastomosis with adjacent veins, or lymph nodes in zone IV were selected for end-to-side anastomosis with the external jugular vein trunk. The Unified Parkinson's Disease Rating Scale was used to measure and assess patients at predetermined time points before and after surgery. Results None of the 8 surgical patients experienced severe complications. Postoperative follow-up results showed significant improvements in motor dysfunction, including enhanced gait stability, reduced tremors, and improved motor coordination. Additionally, cognitive impairments such as sleep quality, emotional stability, and olfactory and gustatory functions also demonstrated some degree of improvement. Conclusions dcLVA improves intracranial lymphatic circulation, reduces intracranial lymphatic pressure, and promotes the clearance of brain metabolic proteins, thereby alleviating clinical symptoms in patients with Parkinson's disease. This provides a novel approach to the treatment of Parkinson's disease.
Key words
Parkinson's disease /
/
/
Deep cervical lymphatic-venous anastomosis /
/
/
Clinical efficacy
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Poewe W, Seppi K, Tanner CM, et al. Parkinson disease[J]. Nat Rev Dis Primers, 2017,3:17013. DOI:10.1038/nrdp.2017.13.
[2] Chen S, Chan P, Sun S, et al. The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease[J]. Transl Neurodegener, 2016,5:12. DOI:10.1186/s40035-016-0059-z.
[3] Gen Li, Jianfang Ma, Shishuang Cui,et al. Parkinson's disease in China: a forty-year growing track of bedside work[J]. Transl Neurodegener, 2019,8:22. DOI: 10.1186/s40035-019-0162-z.
[4] Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease[J]. Mov Disord, 2018,33(8):1248-1266. DOI:10.1002/mds.27372.
[5] Spillantini MG, Goedert M. Synucleinopathies: past, present and future[J]. Neuropathol Appl Neurobiol, 2016,42(1):3-5. DOI:10.1111/nan.12311.
[6] Da Mesquita S, Fu Z, Kipnis J. The meningeal lymphatic system: a new player in neurophysiology[J]. Neuron, 2018, 100(2):375-388. DOI:10.1016/j.neuron.2018.09.022.
[7] Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels[J]. Nature, 2015,523(7560):337-341. DOI:10.1038/nature14432.
[8] Robbins KT, Clayman G, Levine PA, et al. Neck Dissection Classification Update: Revisions Proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery[J]. Arch Otolaryngol Head Neck Surg, 2002,128(7):751-758. DOI:10.1001/archotol.128.7.751.
[9] Steinmetz JD, Seeher KM, Schiess N, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet Neurol, 2024,23(4):344-381. DOI:10.1016/S1474-4422(24)00038-3.
[10]Zhao X, He H, Xiong X, et al. Lewy body-associated proteins a-synuclein (a-syn) as a plasma-based biomarker for Parkinson's disease[J]. Front Aging Neurosci,2022,14:869797. DOI:10.3389/fnagi. 2022.869797.
[11]Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules[J]. J Exp Med, 2015,212(7):991-999. DOI:10.1084/jem.20142290.
[12]Da Mesquita S, Louveau A, Vaccari A, et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease[J]. Nature, 2018,560(7717):185-191. DOI:10.1038/s41586-018-0368-8.
[13]Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia[J]. Science, 2020,370(6512):50-56. DOI:10.1126/science.abb8739.
[14]Patel TK, Habimana-Griffin L, Gao X, et al. Dural lymphatics regulate clearance of extracellular tau from the CNS[J]. Mol Neurodegener, 2019,14(1):11. DOI:10.1186/s13024-019-0312-x.
PDF(2277 KB)
